Q3 2024 Lisata Therapeutics Inc Earnings Call Transcript
Key Points
- Lisata Therapeutics Inc (LSTA) reported a decrease in operating expenses by 10.5% compared to the same period last year, indicating effective cost management.
- The company has a strong cash position with approximately $35.9 million in cash, cash equivalents, and marketable securities, expected to fund operations into early 2026.
- Certepetide has shown promising potential in preclinical and early clinical data as a treatment for advanced solid tumors, including pancreatic and cholangiocarcinoma.
- The ASCEND trial for certepetide in metastatic pancreatic ductal adenocarcinoma has reached a significant milestone with preliminary results to be presented at ASCO GI in January 2025.
- Lisata Therapeutics Inc (LSTA) has received multiple special regulatory designations for certepetide, including orphan drug designation and fast track designation, enhancing its development prospects.
- Despite progress, Lisata Therapeutics Inc (LSTA) is frustrated with its current share price and market valuation, which they believe does not reflect the company's true value.
- The GBM trial has experienced slower than expected enrollment due to delays in site initiation in Latvia.
- General and administrative expenses increased by 8.1% compared to the previous year, primarily due to higher consulting expenses.
- The company faces challenges in patient enrollment for certain trials, particularly in second-line cholangiocarcinoma, due to the poor performance status of patients.
- Lisata Therapeutics Inc (LSTA) acknowledges that its ability to pursue all potential opportunities is limited by available capital.
Welcome to the Lisata Therapeutics' third-quarter 2024 financial results and business update conference call. (Operator Instructions)
As a reminder, this call is being recorded today, Tuesday, November 12, 2024. I would now like to turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Lisata. Please go ahead, sir.
Thank you, operator, and good afternoon, everyone. Welcome to Lisata's third-quarter 2024 conference call to discuss our financial results and to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Senior Vice President of Finance and Treasury and Chief Accounting Officer.
Shortly before this call, we issued a press release announcing our third quarter 2024 financial results, which is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
